title: Pharmaceutical approval update.
abstract: Mirabegron (Myrbetriq) for overactive bladder; phentermine/topiramate ER (Qsymia) for weight management; and ocriplasmin injection (Jetrea) for vitreomacular adhesion.
authors: Marvin M
authors: MM
authors: Goldenberg